LEASE AGREEMENTLease Agreement • October 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 24th day of May, 2007, between ALEXANDRIA REAL ESTATE EQUITIES, INC., a Maryland corporation (“Landlord”), and SPALTUDAQ CORP., a Delaware corporation (“Tenant”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations • Washington
This Executive Employment Agreement (this “Agreement”) is entered into between PharmAthene, Inc., a Delaware corporation (the “Company”), and Clifford J. Stocks (“Executive”). This Agreement is effective as of the day of the closing (the “Closing”) of the merger by and between the Company and Theraclone Sciences, Inc., a Delaware corporation, and certain other parties, (the “Merger”) pursuant to that Agreement and Plan of Merger Dated July 31, 2013 (the “Effective Date”). In the event the Merger is not consummated, this Agreement shall be of no force and effect.
ContractResearch Collaboration Agreement • October 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations
[***] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
AMENDMENT NO. 2 TO RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • October 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations • New York
This Amendment No. 2 to the Research Collaboration Agreement (this Amendment) is dated as of December 3, 2012 (the Effective Date), between:
EMPLOYMENT AGREEMENTEmployment Agreement • October 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations • Maryland
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this [ ] day of [ ] 2013 (the "Effective Date") by and between [ ] (the “Executive”) and PharmAthene, Inc., a Delaware corporation (“PharmAthene” or the “Company”).
AMENDMENT NO. 1 TO RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • October 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations • New York
This Amendment No. 1 to the Research Collaboration Agreement (this Amendment) is dated as of November 30, 2010 (the Effective Date), between:
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • October 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations • New York
This DEVELOPMENT AND LICENSE AGREEMENT (together with the exhibits hereto, the “Agreement”) is entered into as of March 11, 2010 (the “Effective Date”) by and between Theraclone Sciences, Inc., a corporation organized and existing under the laws of the State of Delaware, USA and having its principal office at 1124 Columbia Street, Suite 300, Seattle, Washington, 98104, USA (“Theraclone”) and Zenyaku Kogyo Co., Ltd., a corporation organized and existing under the laws of Japan and having its principal office at 6-15 Otsuka, 5-Chome, Bunkyo-Ku, Tokyo 112-8650, Japan (“ZKC” or “Zenyaku”).
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and betweenResearch Collaboration and License Agreement • October 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations • New York
Each of the Development Payments set forth above shall be payable one time only for each Target, regardless of the number of Products that target the same Target. For clarification, if one Product replaces another Product in Development, then such replacement Product shall only be subject to Development Payments that have not previously been triggered by one or more prior Products. The maximum amount payable by Pfizer in respect of Development Payments if all Development Events occur for any Target shall be [***].
